If you enjoy this content, please share it with a colleague
May 18, 2012 — In April the U.S. Food and Drug Administration (FDA) approved Avid Radiopharmaceuticals’ (now part of Eli Lilly) Amyvid, a brain plaque diagnostic tool using florbetapir (F-AV-45). This radiotracer agent is delivered intravenously and is drawn to beta-amyloid plaque, a characteristic of AD.
Several positron emission tomography (PET) imaging agents are being developed to visualize Alzheimer’s disease in the living brain to accurately diagnose patients and develop effective treatments. The only way to confirm the presence of the disease currently is by examining post-mortem samples of the patient’s brain. Experts predict these agents may soon receive U.S. Food and Drug Administration (FDA) clearance.
July 19, 2011 – The study "Use of Florbetapir-PET for Imaging beta-amyloid Pathology," published in the Jan. 19, 2011, issue of the Journal of the American Medical Association, has been selected by the Alzheimer's Association as the winner of the 2011 de Leon Prize in Neuroimaging for the “Best Paper” award in human neuroimaging, in the Senior Scientist category. The award was presented Saturday, July 16, 2011, to Chris Clark, M.D., co-author of the paper and medical director at Avid Radiopharmaceuticals, a wholly owned subsidiary of Eli Lilly and Co., during the Alzheimer's Imaging Consortium (AIC), in Paris, France. The AIC was a preconference to the Alzheimer's Association International Conference 2011 (AAIC 2011), held from July 17-21, 2011.
January 21, 2011 — The U.S.
October 3, 2007 - Avid Radiopharmaceuticals Inc., a product-focused molecular imaging company, announced today that ...
June 15, 2007 - Avid Radiopharmaceuticals Inc. announced that a preclinical study presented at at the Society of Nuclear ...